Home
NewsNewsLatest development marks a transformative step in endometriosis care by reducing diagnostic delays and enabling earlier treatment for improved patient outcomes. ENDOSURE's rapid and accurate diagnostic capability is expected to benefit thousands of women suffering from this chronic condition across Canada.
EndoDiagnosis has announced that CReATe Fertility is the first clinic in Canada to offer the innovative Tier 1 ENDOSURE diagnostic test for endometriosis, authorized by Health Canada since 2021. This non-invasive diagnostic test provides an accurate and rapid alternative to the traditional gold standard of laparoscopic surgery for diagnosing endometriosis, a chronic and often debilitating inflammatory disease affecting women globally.
The ENDOSURE test offers 99% accuracy, delivering results within 30 minutes during a single clinic visit without the need for referrals or laboratory processing. It detects all types and stages of endometriosis and is suitable for women of all ages, from pre-teens to post-menopausal individuals. This enables healthcare providers to quickly confirm endometriosis as the cause of menstrual or abdominal pain and infertility, which are common symptoms of the disease.
Endometriosis affects at least 10% of women worldwide, yet diagnosis is often delayed by 3 to 11 years due to the limitations and invasiveness of laparoscopy. Many patients endure prolonged suffering without accurate diagnosis because symptoms overlap with other conditions, and pain is sometimes dismissed by clinicians or attributed to normal menstrual discomfort. Tier 1 diagnostic testing like ENDOSURE addresses this diagnostic gap by providing a reliable, pain-free, and fast diagnostic option.
By incorporating ENDOSURE, CReATe Fertility is leading the way in Canadian reproductive healthcare to accelerate diagnosis and treatment. Early identification of endometriosis is critical as it allows for timely symptom management and interventions that can slow or stop disease progression and improve fertility outcomes. The ability to diagnose in real time also helps clinicians monitor patient responses post-treatment and adjust care plans accordingly.
The offering of the Tier 1 ENDOSURE test at CReATe Fertility empowers both patients and healthcare providers with a decision-support tool that transforms the experience of care. Patients gain faster access to answers, reducing years of uncertainty and enabling better quality of life. Clinicians receive actionable diagnostic data to guide personalized treatment pathways without the risks or costs associated with surgery.
This move is part of EndoDiagnosis’ broader mission to revolutionize endometriosis care worldwide by making rapid, accurate, and non-invasive diagnostics accessible. The company supports providers with education and a network to facilitate the adoption of ENDOSURE. With the introduction of this test in Canada, women suffering from chronic pelvic pain and infertility symptoms now have access to state-of-the-art diagnostics that validate their experiences and offer hope for better management.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
